Board meeting today 29 Oct to approve Q2/H1 results (NSE board-meeting intimation, 13 Oct); earnings call 5pm IST (ScanX). Binary event on entry day, after a +109% 6m run with price 11.9% above EMA50 at a 52-week high. No entry before results.
Claude as risk reviewer
Analyst calls
For every stock the momentum screen proposes, the analyst checks results dates, exchange filings and recent news, then rates it. Underweight or Sell at 55% confidence or more blocks the buy, Hold shrinks it, Buy and Overweight mean no objection. Every reason cites its source.
Calls made172 review sessions
Blocking calls4Underweight/Sell ≥ 55%
Size cuts7Hold ratings
No objection6Buy / Overweight
NSEData to Wed, 28 Oct 2026
Full report with sources →Yahoo's 28 Oct bar is missing (NaN), so trend, RSI and the SEPA checklist cannot be verified today. Results due 7 Nov (NSE calendar). No red flags found; last close near the 52-week high (Rs 9,740). Hold until data is clean.
SEPA 7/7, RS +21% vs Nifty over 3m, 4.8% from the 52-week high. Results 6 Nov (NSE calendar), 6 trading days away. No negative filings or news found (NSE filings to 26 Oct are routine).
Q2 FY27 (16 Oct): record net profit Rs 1,386 cr (+45% y/y), NII +26%, NIM 3.32%, gross NPA 1.32% and net NPA 0.17% at decade lows (Upstox, Free Press Journal). SEPA 7/7; results already out, so no event risk.
SEPA 7/7, RS +9% over 3m, 2% below the 52-week high, but Q2 results on 4 Nov (NSE calendar), 4 trading days after entry: gap risk inside the first week. Size down.
Positive: USFDA approval announced 21 Oct (NSE press release); SEPA 7/7, RS +12% over 3m. But Q2 results on 4 Nov (NSE calendar), 4 trading days after entry. Size down.
Filed Q2 results on 28 Oct (NSE outcome of board meeting, 12:41). Numbers and analyst reaction not yet available in news search, so the results are unverified. Price flat (1m -1.5%), only 0.8% above EMA50. Wait for the reaction.
Q2 FY27 (21 Oct): profit +92% to Rs 125 cr and revenue +78%, but profit missed expectations and shares fell ~3.5% (Kotak Neo, IndMoney). 12m return -0.9%, 1m -2.7%. Mixed: no veto, no conviction.
SEPA 7/7, RS +11% over 3m, 4.9% from the 52-week high. Results 12 Nov (NSE calendar), well outside the entry window. Director change filed 28 Oct (routine). No red flags found.
USData to Tue, 27 Oct 2026
Momentum rank #1 on 6/12m returns but fading now: -6.6% in 1m, RSI 40, RS -3.3% over 3m, trend template 6/7. Q3 results expected around mid-November (not confirmed). Not a clean entry today.
Q3 results on Thu 29 Oct, 9am ET call (24/7 Wall St, 28 Oct); Seeking Alpha preview expects EPS down 19% to 2.09. Binary event tomorrow: no new entry.
Trend template 7/7, 3.5% below the 52-week high; Q3 results Wed 4 Nov after the close (MetLife newsroom), 5 trading days away, so size down rather than full entry.
Fiscal Q4 results Mon 2 Nov after the close (Apple announcement via MacTrast, Oct 2026), 3 trading days away; trend template 7/7 and near the 52-week high, but earnings gap risk inside the holding window.
Q3 reported 13 Oct (EPS 2.59 vs 2.53 consensus per Nasdaq calendar listing; not independently verified). Trend template 7/7, 3.5% below the 52-week high, no upcoming event found; relative strength slightly negative over 3m.
Trend template 7/7, up 4.8% in 1m; fiscal Q1 results usually mid-November (date not yet confirmed in search), so no event in the next week. Weak point: 13.7% below the 52-week high and RS -6% over 3m.
Q3 reported 27 Oct: EPS 0.91 vs ~0.88 consensus, revenue 13.4B (+7% y/y), full-year comparable EPS growth outlook raised to at least 11% (Alphastreet; call transcript via Seeking Alpha). Trend template 7/7, low volatility (ATR 1.7%). Event risk already passed.
Q3 results on Thu 29 Oct, 10am ET call (Lilly press release via MarketScreener); consensus EPS estimates are unsettled (6.67 vs 9.92 across providers), so binary gap risk is high. Veto new entry until after results.